GLP-1-based clinical therapies have firmly established their importance among the therapeutical approaches available for the treatment of type 2 diabetes [40–42]; their action is exerted by potentiating glucose-stimulated insulin secretion. This evidence concerns the gene GCG and type 2 diabetes mellitus.